SynthesisWorld neurosurgery2023
Effect of Extent of Resection on Survival of Patients with Glioblastoma, IDH-Wild-Type, WHO Grade 4 (WHO 2021): Systematic Review and Meta-Analysis.
Synthesis in World neurosurgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Surgical treatment of recurrent glioblastoma: a multicenter perspective from the Italian society of neurosurgery (SINchNeurosurgical review · 2026Pooled it
- Comparative efficacy of glioma treatment strategies: an umbrella review of meta-analyses.Annals of medicine · 2025Pooled it
- Intraoperative ultrasound for surgical resection of high-grade glioma and glioblastoma: a meta-analysis of 732 patients.Neurosurgical review · 2024Pooled it
- Evaluating "brain permeability": A critical issue for the development of therapeutic agents for primary and metastatic brain tumors.Neuro-oncology · 2026Review
- Tunable Technologies for the Glioma Tumor Microenvironment: A Comprehensive Review on Bench-to-Bedside Neurosurgical Advances.Brain sciences · 2026Review
- High-to-Low Spectral Mapping for Cross-System Feature Adaptation in Medical Hyperspectral Imaging.Bioengineering (Basel, Switzerland) · 2026Article
- Review
- Extent of Resection and Survival in IDH-Wildtype Glioblastoma: A Dual-Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2026Article
- Awake Craniotomy Versus General Anesthesia for Resection of High-Grade Gliomas: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Effect of navigated transcranial magnetic stimulation for glioma surgery outcomes: a systematic review and meta-analysis.Open medicine (Warsaw, Poland) · 2026Article
- Extent of reoperation predicts survival in recurrent IDH-wildtype glioblastoma based on institutional data and individual patient data meta analysis.Discover oncology · 2025Article
- Review
- High-precision intraoperative diagnosis of gliomas: integrating imaging and intraoperative flow cytometry with machine learning.Frontiers in neurology · 2025Article
- Customized SAM-Med3D with multi-view adapter and T2-FLAIR mismatch features for glioma IDH genotyping and grading.Frontiers in behavioral neuroscience · 2025Article
- Risk Factors Involved in the Blood (Leukocyte-Depleted Suspended Red Blood Cells and Plasma) Transfusion During Glioma Operations.Journal of blood medicine · 2025Article
- Cytocidal Effects of Interstitial Photodynamic Therapy Using Talaporfin Sodium and a Semiconductor Laser in a Rat Intracerebral Glioma Model.Biomedicines · 2024Article
- Molecular Profile as an Outcome Predictor in Glioblastoma along with MRI Features and Surgical Resection: A Scoping Review.International journal of molecular sciences · 2024Article
- Challenges and Opportunities in Accessing Surgery for Glioblastoma in Low-Middle Income Countries: A Narrative Review.Cancers · 2024Article
- Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management.Scientific reports · 2024Article
- Efficacy of interstitial photodynamic therapy using talaporfin sodium and a semiconductor laser for a mouse allograft glioma model.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundIn light of the recently updated World Health Organization (WHO) 2021 central nervous system tumor classifications, the aim of the present study was to establish the effect of the resection extent on overall survival (OS) and progression-free survival (PFS) for patients who met the current diagnostic criteria for glioblastoma, isocitrate dehydrogenase (IDH)-wild-type (WT), WHO grade 4.
methodsA systematic literature search was performed using the following databases: PubMed, Web of Science, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews and ClinicalTrials.gov to identify studies that had compared OS and PFS after gross total resection (GTR) versus subtotal resection (STR) or biopsy for glioblastoma IDH-WT.
resultsWe identified 1439 studies, of which 9 met the inclusion and/or exclusion criteria. Of the 2023 patients, 788 had undergone GTR. The meta-analysis showed a significant increase in the OS and PFS duration after GTR for glioblastoma IDH-WT, with a median OS of 20 months (95% confidence interval [CI], 17-25) after GTR versus 12 months (95% CI, 9-15) after STR (P < 0.0001). The median PFS was 11 months (95% CI, 9-12) after GTR versus 7 months (95% CI, 5-7) after STR (P < 0.0001). GTR was associated with a 51% reduction in the mortality risk (hazard ratio, 0.49; 95% CI, 0.36-0.65) and a 42% reduction in the progression risk (hazard ratio, 0.58; 95% CI, 0.39-0.88) compared with STR.
conclusionsThe results from our systematic review suggest that GTR is associated with improved OS and PFS compared with STR for glioblastoma, IDH-WT, WHO grade 4 (WHO 2021). However, our findings were limited by the various study designs and significant clinical and methodologic heterogeneity among the studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.